These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 18690345

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone.
    Hellgren M, Conard J, Norris L, Kluft C.
    Maturitas; 2009 Mar 20; 62(3):287-93. PubMed ID: 19268506
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.
    Hemelaar M, Rosing J, Kenemans P, Thomassen MC, Braat DD, van der Mooren MJ.
    Arterioscler Thromb Vasc Biol; 2006 Jul 20; 26(7):1660-6. PubMed ID: 16645152
    [Abstract] [Full Text] [Related]

  • 6. Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study.
    Sidelmann JJ, Jespersen J, Andersen LF, Skouby SO, Prospective Collaborative Danish Climacteric Study.
    BJOG; 2003 Jun 20; 110(6):541-7. PubMed ID: 12798469
    [Abstract] [Full Text] [Related]

  • 7. Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.
    Połać I, Borowiecka M, Wilamowska A, Nowak P.
    Gynecol Endocrinol; 2013 Feb 20; 29(2):165-8. PubMed ID: 23116237
    [Abstract] [Full Text] [Related]

  • 8. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
    Hemelaar M, Kenemans P, Hack CE, Klipping C, van der Mooren MJ.
    Menopause; 2008 Feb 20; 15(2):248-55. PubMed ID: 17693902
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of two oral doses of 17beta-estradiol associated with dydrogesterone on thrombin generation in healthy menopausal women: a randomized double-blind placebo-controlled study.
    Rousseau A, Robert A, Gerotziafas G, Torchin D, Zannad F, Lacut K, Libersa C, Dasque E, Démolis JL, Elalamy I, Simon T.
    Fundam Clin Pharmacol; 2010 Apr 20; 24(2):239-45. PubMed ID: 19719551
    [Abstract] [Full Text] [Related]

  • 11. Effect of hormone replacement therapy on hemostatic variables in post-menopausal women.
    Al-Farra HM, Al-Fahoum SK, Tabbaa MA.
    Saudi Med J; 2005 Dec 20; 26(12):1930-5. PubMed ID: 16380775
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
    Jespersen J.
    Dan Med Bull; 1988 Feb 20; 35(1):1-33. PubMed ID: 3277796
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term effects of low-dose 17beta-estradiol plus dydrogesterone on 24-h ambulatory blood pressure in healthy postmenopausal women: a 1-year, randomized, prospective study.
    Kaya C, Cengiz SD, Cengiz B, Akgun G.
    Gynecol Endocrinol; 2007 Oct 20; 23 Suppl 1():62-7. PubMed ID: 17943541
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Differential effect of the ultra-low dose and standard estrogen plus dydrogesterone therapy on thrombin generation and fibrinolysis in postmenopausal women.
    Piróg M, Jach R, Kacalska-Janssen O.
    Acta Obstet Gynecol Scand; 2017 Dec 20; 96(12):1438-1445. PubMed ID: 28981954
    [Abstract] [Full Text] [Related]

  • 20. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
    Eilertsen AL, Liestøl S, Mowinckel MC, Hemker HC, Sandset PM.
    Thromb Haemost; 2007 Jun 20; 97(6):938-43. PubMed ID: 17549295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.